Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1316 • ACR Convergence 2025
Predicting mortality of rheumatoid arthritis in China: A nation-wide cohort study
Kangping Huang¹, Shixiong Wei², Lan Zhang³, Xinhao Li², Mucong Li², Chen Yu⁴, Nan Jiang², Jiuliang Zhao², Yanhong Wang⁵, Chanyuan Wu², Peng Yin⁶, Qian Wang², Mengtao Li², Xinping Tian² and Xiaofeng Zeng⁷, ¹Peking Union Medical College, Beijing, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ³School of Public Health, Peking University, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁶National Center for Chronic and NCD Control and Prevention, Chinese Center for Disease Control and Prevention, Xicheng, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with increased mortality, primarily due to systemic inflammation and comorbidities. While previous studies have identified…
Abstract Number: 1238 • ACR Convergence 2025
Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
Nadine El-ayache¹, Sayuli Bhide², Hannah Brubeck³, Punyasha Roul⁴, Bryant England⁵, Joshua Baker⁶, Grant Cannon⁷, Namrata Singh⁸, Gary Kunkel⁹, Ted Mikuls⁵, Patti Katz¹⁰, Dolores Shoback¹¹, Jose Garcia¹², Pradeep Suri¹³, Marianna Gasperi¹³, Ariela Orkaby¹⁴, Una Makris¹⁵ and Katherine Wysham¹⁶, ¹VA Puget Sound Health Care System & University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴UNMC, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Washington, Bellevue, WA, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰UCSF, San Rafael, CA, ¹¹San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ¹²VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, ¹⁴VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ¹⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty, an increased vulnerability to stressors, is commonly associated with aging and functional decline. Pain, prevalent among older adults, contributes to frailty in the…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 1007 • ACR Convergence 2025
Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis
adeep Kulkarni¹, Jose Scher², Rebecca Haberman³ and Souptik Barua¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New York, NY
Background/Purpose: Patients with inflammatory arthritis (IA) report reduced physical activity and poor sleep, However, much remains unknown about the extent and impact of this relationship.…
Abstract Number: 0906 • ACR Convergence 2025
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
Abstract Number: 0817 • ACR Convergence 2025
More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Patients with rheumatic diseases commonly experience acute or chronic pain that may lead to both short- and long-term opioid use. Many patients do not…
Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 0485 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Rheumathoid Arthritis (RA) is a chronic inflammatory disease that affects the musculoskeletal system. Early and effective treatment is important to improve the quality of…
Abstract Number: 0469 • ACR Convergence 2025
Evaluating Large Language Models for Automated Joint Involvement Analysis in Rheumatoid Arthritis
Xingyi Liu¹, Sunghwan Sohn¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN
Background/Purpose: In rheumatoid arthritis (RA), delaying initiation of treatment for 12 weeks or longer may lead to permanent joint damage and make remission harder to…
Abstract Number: 0452 • ACR Convergence 2025
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Keigo Hayashi¹, Kei Hirose², Natsuki Kubota¹, Yuya Terajima¹, Kazuya Matsumoto¹, Takato Nakadoi¹, Shoichi Nawachi¹, Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama¹, Haruki Watanabe¹, Mariko Narazaki¹, Yoshinori Matsumoto¹ and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) and osteoporosis management that have improved patient outcomes, osteoporosis continues to be a significant clinical concern in RA.…
Abstract Number: 0435 • ACR Convergence 2025
Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study
Ahmad Alomari¹, Reem Elmusa², Nikita Shah³, Miguel Rodriguez⁴ and Diala Alawneh⁵, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/ HCA - North florida hospital, Gainesville, FL, ³UCF/HCA Florida North Florida Hospital, Gainesville, FL, ⁴SIMED Rheumatology, Gainesville, FL, ⁵University of Florida, Gainesville, FL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Stefano Gentileschi¹, Carla Gaggiano¹, Francesco Placido¹, Riccardo Terribili¹, Laura Cometi², Giuseppe Lopalco³, Greta Dipetrangelo³, Giacomo Cozzi⁴, Roberto Padoan⁵, Riccardo Bixio⁶, Simone Parisi⁷, Maria Chiara Ditto⁸, Gemma Lepri⁹, Caludia Fabiani¹⁰, Luca Cantarini¹, Florenzo Iannone¹¹, Roberta Ramonda¹², Bruno Frediani¹ and Serena Guiducci², ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy, ²Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ³Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University o f Bari, Bari, Italy, Bari, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, Padua, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ⁶Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, Verona, Italy, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸SC Reumatologia, AOU Città della Salute e della Scienza, Torino, Italy, Turin, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹⁰Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, Siena, Italy, ¹¹Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹²Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…
Abstract Number: 0173 • ACR Convergence 2025
Association Between the Ratio of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol and All-Cause Mortality Risk in Patients with Rheumatoid Arthritis: A Survival Analysis Based on NHANES Data
Tingting Wang¹, Siying Xiong¹, Yuanli Wei¹, Dongmei Wang¹, Weihua Zhang¹, Caizhen Liu², Fanxin zeng³ and Jianhong Wu¹, ¹Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, China (People's Republic), ²Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, ³Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital; Medical School, Sichuan University of Arts and Sciences; School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Dazhou, China (People's Republic)
Background/Purpose: The Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio (NHHR) has emerged as a promising marker for atherosclerosis, yet its relationship with all-cause mortality…
Abstract Number: 0090 • ACR Convergence 2025
Interleukin-36β modulates the progression of rheumatoid arthritis by altering the behavior of rheumatoid arthritis synovial fibroblasts
Marie Svenja Kümmel¹, Mona Arnold-Gräf², Selina Ohl², Klaus Frommer³, Nils Schulz⁴, Stefan Rehart⁵, Ulf Müller-Ladner³ and Elena Neumann³, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Gießen, Germany, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Germany, ³Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Hessen, Germany, ⁴Kerkchoff Klinik, Dep. of rheumatology, Bad Nauheim, Germany, ⁵Agaplesion Markus Hospital, Frankfurt, Hessen, Germany
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASF) play a central role in driving inflammation and promoting cartilage degradation in Rheumatoid arthritis (RA). In our study, we…
Abstract Number: 0071 • ACR Convergence 2025
Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
Chary López pedrera¹, Tomás Cerdó², Ismael Sanchez-Pareja², Daniel Toro³, MARIA ANGELES AGUIRRE ZAMORANO², Elena Moreno-Caño⁴, Laura muñoz-Barrera², Sagrario Corrales², Rafaela Ortega-Castro⁵, Concepción Aranda-Valera⁶, Lourdes Ladehesa⁷, Jerusalén Calvo⁶, Pilar Font⁸, M Carmen Abalos-Aguilera⁹, Desiree Ruiz-Vilchez¹⁰, Christian Merlo-Ruiz⁹, Nuria Barbarroja¹¹, Carlos Pérez Sánchez¹², Marta Alarcon-Riquelme¹³ and Alejandro Escudero Contreras⁶, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹⁰Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: This study aimed to identify shared and distinct gene and protein expression profiles associated with clinical features in rheumatoid arthritis (RA), systemic lupus erythematosus…

« Previous Page
1
…
4
5
6
7
8
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].